Enable Accessibility
Enable Accessibility
Better Health,
Brighter Future
Newsroom
Careers
Investors
United States
Who We Are
About Takeda
How can we do more for our patients?
Everything at Takeda starts with this question.
Learn more
Company Information
Takeda in the U.S.
Worldwide Offices
Executive Leadership
Corporate Philosophy
Contact Us
What We Do
Our Business
Takeda continues its transformation into an agile and innovative global pharmaceutical leader, serving the needs of patients and physicians worldwide.
Learn more
Research & Development
Our Pipeline
Therapeutic Areas
Patient Services
U.S. Product List
Our Stories
Our Stories
A selection of stories related to Innovation, Caring and Heritage
Learn more
Innovation
In Their Shoes
The Key Elements at the Heart of Our Innovation
Partnerships as Catalysts for Innovation
Caring
Medicine for the World
Heritage
Keys to Aging Gracefully
Corporate Responsibility
Takeda's CSR
Takeda is committed to creating corporate value by developing outstanding pharmaceutical products and conducting corporate citizenship activities.
Learn more
Commitment to Community
Our Environment
Culture of Compliance
Federal
CPSIA
State
Open Payments and Transparency Reporting
Diversity and Inclusion
Independent Medical Education Grants
Takeda Pricing Philosophy
Lobbying & Political Contributions
Patient Assistance
ADHD Medicines Misuse
HOME
Newsroom
News Releases
Share:
Newsroom
News Releases
Statements
NATPARA Updates
COVID-19 Updates
News Releases
Enter
All
Last 12 months
2017
2016
2015
2014
2013
2012
2009
2008
2007
2005
2004
2003
2002
2000
December 2020
December 15, 2020
12/15/2020
U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda’s TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis
December 2, 2020
12/2/2020
TAKEDA FURTHER ENABLES HEMOPHILIA A PERSONALIZED CARE WITH LAUNCH OF MYPKFIT® SOFTWARE FOR ADYNOVATE ® [ANTIHEMOPHILIC FACTOR (RECOMBINANT), PEGYLATED]
November 2020
November 9, 2020
11/9/2020
Takeda to Highlight Research Commitment in Bleeding Disorders and Personalized Care at American Society of Hematology (ASH) Virtual Annual Meeting
October 2020
October 27, 2020
10/27/2020
Takeda to Present Rare Bleeding Disorders Research at Thrombosis & Hemostasis Summit of North America (THSNA) 2020
August 2020
August 10, 2020
8/10/2020
National Hemophilia Foundation and Takeda Partner with Alex Borstein to Raise Awareness of von Willebrand Disease
August 1, 2020
8/1/2020
Takeda to Present Rare Bleeding Disorders Research Highlighting Need for Real-World Evidence at NHF Bleeding Disorders Conference 2020
April 2020
April 23, 2020
4/23/2020
ProThera Biologics and Takeda Enter Global Licensing Agreement
April 16, 2020
4/16/2020
USBU COVID-19 Supply Statement
1
2
3
4
5
TOP